4556.T
KAINOS Laboratories,Inc.
スタンダード · 医薬品 · 医薬品 · JP
JPY 2,268.00
+0.00%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.5B | 5.5B | 5.3B | 5.1B | 4.9B |
| Cost of Revenue | 691.9M | 2.9B | 2.6B | 2.5B | 2.4B |
| Gross Profit | 740.1M | 2.6B | 2.7B | 2.6B | 2.5B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 483.6M | 1.8B | 1.9B | 1.7B | 1.7B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 483.6M | 1.8B | 1.9B | 1.7B | 1.7B |
| Cost and Expenses | 4.7B | 4.7B | 4.5B | 4.2B | 4.1B |
| Operating Income (EBIT) | 748.0M | 747.0M | 823.0M | 865.0M | 821.0M |
| Non-Operating | |||||
| Interest Income | — | 1.7M | 372.0K | 24.0K | 22.0K |
| Interest Expense | 1.6M | 6.2M | 6.6M | 7.0M | 7.6M |
| Net Interest Income | — | (4.6M) | (6.2M) | (7.0M) | (7.5M) |
| Other Non-Op Income/Expense | 1.8M | 41.1M | 4.6M | 63.3M | 32.9M |
| Non-Operating Income (excl Interest) | 348.0K | 79.3M | 12.9M | 106.6M | 40.9M |
| EBT (Pre-Tax Income) | 258.3M | 634.2M | 827.2M | 930.1M | 845.2M |
| Income Tax Expense | 74.7M | 185.0M | 186.1M | 292.1M | 277.0M |
| Bottom Line | |||||
| Net Income | 597.0M | 449.0M | 641.0M | 637.0M | 568.0M |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 597.0M | 449.0M | 641.0M | 637.0M | 568.0M |
| Per Share | |||||
| Basic EPS | ¥142 | ¥106 | ¥152 | ¥152 | ¥136 |
| Diluted EPS | ¥142 | ¥106 | — | — | — |
| Revenue Per Share | ¥1,294 | ¥1,295 | ¥1,258 | ¥1,207 | ¥1,179 |
| Shares | |||||
| Basic Shares Outstanding | 4.2M | 4.2M | 4.2M | 4.2M | 4.2M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 849.6M | 926.1M | 983.7M | 962.5M |
| D&A | — | 102.6M | 103.1M | 118.7M | 141.5M |
| EBIT | 748.0M | 747.0M | 823.0M | 865.0M | 821.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026